FIRECREST training solutions used worldwide by all top ten pharma
in 1,100+ studies
DUBLIN--(BUSINESS WIRE)--
ICON plc, (NASDAQ: ICLR) a global provider of drug development
solutions and services to the pharmaceutical, biotechnology and medical
device industries, today announced that its FIRECREST solutions have won
gold and silver awards for eLearning and digital animation. FIRECREST
was awarded gold in the International
eLearning Awards (IELA) in the blended learning category, and
received a silver award for digital animation in the Summit
International Awards.
The annual International E-Learning Awards recognise excellence in
e-learning, mobile learning and blended learning in academia and
business. ICON's Protocol Overview, which is part of the FIRECREST
Investigator Portal, was judged as the best blended learning solution.
Protocol Overview uses graphics, audio, animation and other interactive
tools to help investigators and site staff to quickly process, retain
and apply study-specific information to clinical trials. It enables
self-paced access to relevant information, accommodating differing
levels of knowledge and experience of investigators and other site
staff. Protocol Overview has been implemented by the industry's top ten
pharma companies in over 1,100 Ph I-IV studies in over 70 countries.
The annual Summit International Awards recognise excellence and
creativity in marketing communications. ICON's hyperreal,
3D animated video showcased a variety of creative design techniques
that educate study personnel on disease pathology and the
investigational product's mechanism of action.
Commenting on both awards, ICON's VP FIRECREST, Mark Connolly said: "We
are delighted to win such prestigious awards and to be recognized once
again for our innovative training and study management solutions. Our
FIRECREST solutions bring together in-depth clinical research expertise
with industry leading instructional design, graphic and multimedia
capabilities to deliver a truly engaging experience for sponsors, study
teams, sites and patients. Our customers are benefiting from reduced
training & compliance costs, increased consistency in trial execution,
and reductions in preventable errors and protocol deviations."
To learn more about ICON's FIRECREST suite of solutions, visit www.iconplc.com/firecrest
About ICON plc
ICON plc is a global provider of drug development solutions and services
to the pharmaceutical, biotechnology and medical device industries. The
company specialises in the strategic development, management and
analysis of programs that support clinical development - from compound
selection to Phase I-IV clinical studies. With headquarters in Dublin,
Ireland, ICON currently, operates from 87 locations in 38 countries and
has approximately 12,300 employees.
Further information is available at www.iconplc.com
ICON/ICLR-G
This press release contains forward-looking statements. These
statements are based on management's current expectations and
information currently available, including current economic and industry
conditions. These statements are not guarantees of future performance or
actual results, and actual results, developments and business decisions
may differ from those stated in this press release. The forward-looking
statements are subject to future events, risks, uncertainties and other
factors that could cause actual results to differ materially from those
projected in the statements, including, but not limited to, the ability
to enter into new contracts, maintain client relationships, manage the
opening of new offices and offering of new services, the integration of
new business mergers and acquisitions, as well as economic and global
market conditions and other risks and uncertainties detailed from time
to time in SEC reports filed by ICON, all of which are difficult to
predict and some of which are beyond our control. For these reasons, you
should not place undue reliance on these forward-looking statements when
making investment decisions. The word "expected" and variations of such
words and similar expressions are intended to identify forward-looking
statements. Forward-looking statements are only as of the date they are
made and we do not undertake any obligation to update publicly any
forward-looking statement, either as a result of new information, future
events or otherwise. More information about the risks and uncertainties
relating to these forward-looking statements may be found in SEC reports
filed by ICON, including its Form 20-F, F-1, S-8 and F-3, which are
available on the SEC's website at http://www.sec.gov.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170706005457/en/
ICON Media Contact
Camille Frederix
Weber Shandwick
+44
(0) 207 067 0272
cfrederix@webershandwick.com
Source: ICON plc
News Provided by Acquire Media
